A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
暂无分享，去创建一个
U. Banerji | C. Twelves | R. Baird | A. Armstrong | E. Ciruelos | T. Klinowska | J. Garcia-Corbacho | Mafalda Oliveira | R. Maudsley | J. Lindemann | E. Hamilton | T. Brier | C. Hernando | S. Fox | Danielle Carroll | M. Patel | R. Mather | Andy P. Sykes | Jason Incorvati | Sam McGuinness